Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 8.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,612,964 shares of the company's stock after selling 248,702 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 4.40% of Twist Bioscience worth $121,424,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $34,000. Signaturefd LLC lifted its holdings in shares of Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company's stock valued at $36,000 after purchasing an additional 306 shares in the last quarter. Beaird Harris Wealth Management LLC purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $95,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Twist Bioscience by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock valued at $98,000 after purchasing an additional 381 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after purchasing an additional 1,226 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Scotiabank upped their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a "sector outperform" rating in a research note on Tuesday, February 4th. TD Cowen reissued a "buy" rating and set a $58.00 price objective on shares of Twist Bioscience in a research note on Tuesday, November 26th. Barclays cut their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Wolfe Research started coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They set an "outperform" rating and a $60.00 price target on the stock. Finally, Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $53.80.

Twist Bioscience Stock Down 1.8 %

TWST stock traded down $0.83 during mid-day trading on Wednesday, hitting $45.37. 1,182,667 shares of the company were exchanged, compared to its average volume of 846,738. The company has a market capitalization of $2.71 billion, a PE ratio of -13.42 and a beta of 1.87. The company has a current ratio of 4.96, a quick ratio of 4.54 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The firm has a fifty day simple moving average of $48.64 and a 200 day simple moving average of $45.98.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same period last year, the business earned ($0.75) EPS. The firm's revenue for the quarter was up 24.1% compared to the same quarter last year. On average, research analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

Insider Transactions at Twist Bioscience

In related news, SVP Paula Green sold 860 shares of Twist Bioscience stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the sale, the senior vice president now directly owns 133,715 shares in the company, valued at $7,046,780.50. This trade represents a 0.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert Chess sold 2,940 shares of Twist Bioscience stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the sale, the director now owns 18,173 shares in the company, valued at approximately $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 37,180 shares of company stock worth $1,821,971. 3.01% of the stock is currently owned by insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.